FI943231A - Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnoksia - Google Patents
Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnoksia Download PDFInfo
- Publication number
- FI943231A FI943231A FI943231A FI943231A FI943231A FI 943231 A FI943231 A FI 943231A FI 943231 A FI943231 A FI 943231A FI 943231 A FI943231 A FI 943231A FI 943231 A FI943231 A FI 943231A
- Authority
- FI
- Finland
- Prior art keywords
- amino acid
- cys
- lys
- acid residues
- asp
- Prior art date
Links
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 6
- 210000004899 c-terminal region Anatomy 0.000 abstract 2
- LBFYTUPYYZENIR-GHCJXIJMSA-N Asp-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N LBFYTUPYYZENIR-GHCJXIJMSA-N 0.000 abstract 1
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 abstract 1
- 102000002734 Collagen Type VI Human genes 0.000 abstract 1
- 108010043741 Collagen Type VI Proteins 0.000 abstract 1
- AMRLSQGGERHDHJ-FXQIFTODSA-N Cys-Ala-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMRLSQGGERHDHJ-FXQIFTODSA-N 0.000 abstract 1
- RJONUNZIMUXUOI-GUBZILKMSA-N Glu-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N RJONUNZIMUXUOI-GUBZILKMSA-N 0.000 abstract 1
- PKYAVRMYTBBRLS-FXQIFTODSA-N Glu-Cys-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O PKYAVRMYTBBRLS-FXQIFTODSA-N 0.000 abstract 1
- YPLVCBKEPJPBDQ-MELADBBJSA-N Lys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N YPLVCBKEPJPBDQ-MELADBBJSA-N 0.000 abstract 1
- QFSYGUMEANRNJE-DCAQKATOSA-N Lys-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N QFSYGUMEANRNJE-DCAQKATOSA-N 0.000 abstract 1
- VMVNCJDKFOQOHM-GUBZILKMSA-N Ser-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N VMVNCJDKFOQOHM-GUBZILKMSA-N 0.000 abstract 1
- XSEPSRUDSPHMPX-KATARQTJSA-N Thr-Lys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O XSEPSRUDSPHMPX-KATARQTJSA-N 0.000 abstract 1
- GDPDVIBHJDFRFD-RNXOBYDBSA-N Trp-Tyr-Tyr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GDPDVIBHJDFRFD-RNXOBYDBSA-N 0.000 abstract 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 abstract 1
- 108010087924 alanylproline Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 108010003700 lysyl aspartic acid Proteins 0.000 abstract 1
- 108010009298 lysylglutamic acid Proteins 0.000 abstract 1
- 108010038320 lysylphenylalanine Proteins 0.000 abstract 1
- 239000003001 serine protease inhibitor Substances 0.000 abstract 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK9200005 | 1992-01-07 | ||
| PCT/DK1993/000002 WO1993014119A1 (en) | 1992-01-07 | 1993-01-07 | Human kunitz-type protease inhibitor variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI943231A0 FI943231A0 (fi) | 1994-07-06 |
| FI943231A true FI943231A (fi) | 1994-07-06 |
Family
ID=8153776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI943231A FI943231A (fi) | 1992-01-07 | 1994-07-06 | Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnoksia |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5629176A (fi) |
| EP (1) | EP0621869B1 (fi) |
| JP (1) | JPH07506334A (fi) |
| AT (1) | ATE152129T1 (fi) |
| AU (1) | AU671611B2 (fi) |
| CA (1) | CA2127248A1 (fi) |
| CZ (1) | CZ164694A3 (fi) |
| DE (1) | DE69310141D1 (fi) |
| FI (1) | FI943231A (fi) |
| HU (1) | HUT70292A (fi) |
| IL (1) | IL104327A0 (fi) |
| NO (1) | NO942552L (fi) |
| NZ (1) | NZ246567A (fi) |
| RU (1) | RU94036776A (fi) |
| WO (1) | WO1993014119A1 (fi) |
| ZA (1) | ZA9398B (fi) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060134087A1 (en) * | 1988-09-02 | 2006-06-22 | Dyax Corp. | ITI-D1 Kunitz domain mutants as hNE inhibitors |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US5795954A (en) * | 1994-03-04 | 1998-08-18 | Genentech, Inc. | Factor VIIa inhibitors from Kunitz domain proteins |
| CA2220497A1 (en) * | 1995-05-08 | 1996-11-14 | Scios, Inc. | Kunitz type protease inhibitors |
| ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| US5780265A (en) * | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
| US5786328A (en) * | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
| US6242414B1 (en) | 1995-06-07 | 2001-06-05 | Chiron Corporation | Regulation of cytokine synthesis and release |
| US5736364A (en) * | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
| ATE477020T1 (de) | 2002-06-07 | 2010-08-15 | Dyax Corp | Prevention und verringerung von ischemia |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| DE602004031589D1 (de) * | 2003-01-07 | 2011-04-14 | Dyax Corp | Kunitz-domäne-bibliothek |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| SI1981519T1 (en) | 2005-12-29 | 2018-05-31 | Dyax Corp. | INHIBITION PROTEAZE |
| WO2009026334A2 (en) * | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| DK2379096T3 (da) | 2008-12-19 | 2019-11-25 | Baxalta GmbH | TFPI-inhibitorer og fremgangsmåder til anvendelse |
| US8450275B2 (en) | 2010-03-19 | 2013-05-28 | Baxter International Inc. | TFPI inhibitors and methods of use |
| AU2010203712A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| JP6037841B2 (ja) * | 2010-01-06 | 2016-12-07 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
| AU2012204202A1 (en) | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
| HUE046572T2 (hu) | 2012-03-21 | 2020-03-30 | Baxalta GmbH | TFPI inhibitorok és alkalmazási eljárások |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| CN108602893A (zh) | 2015-12-11 | 2018-09-28 | 戴埃克斯有限公司 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3912638A1 (de) * | 1989-04-18 | 1990-10-31 | Bayer Ag | Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel |
| EP0401508B1 (de) * | 1989-05-13 | 1994-11-23 | Bayer Ag | Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
| US5278285A (en) * | 1990-02-01 | 1994-01-11 | Bayer Aktiengesellschaft | Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology |
-
1993
- 1993-01-06 IL IL104327A patent/IL104327A0/xx unknown
- 1993-01-07 RU RU94036776/13A patent/RU94036776A/ru unknown
- 1993-01-07 HU HU9401993A patent/HUT70292A/hu unknown
- 1993-01-07 AU AU33457/93A patent/AU671611B2/en not_active Ceased
- 1993-01-07 ZA ZA9398A patent/ZA9398B/xx unknown
- 1993-01-07 DE DE69310141T patent/DE69310141D1/de not_active Expired - Lifetime
- 1993-01-07 EP EP93902103A patent/EP0621869B1/en not_active Expired - Lifetime
- 1993-01-07 WO PCT/DK1993/000002 patent/WO1993014119A1/en not_active Application Discontinuation
- 1993-01-07 NZ NZ246567A patent/NZ246567A/en unknown
- 1993-01-07 CA CA002127248A patent/CA2127248A1/en not_active Abandoned
- 1993-01-07 AT AT93902103T patent/ATE152129T1/de not_active IP Right Cessation
- 1993-01-07 JP JP5511990A patent/JPH07506334A/ja active Pending
- 1993-01-07 CZ CZ941646A patent/CZ164694A3/cs unknown
-
1994
- 1994-07-06 FI FI943231A patent/FI943231A/fi unknown
- 1994-07-06 NO NO942552A patent/NO942552L/no unknown
- 1994-11-04 US US08/334,773 patent/US5629176A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CZ164694A3 (en) | 1994-12-15 |
| FI943231A0 (fi) | 1994-07-06 |
| ATE152129T1 (de) | 1997-05-15 |
| AU671611B2 (en) | 1996-09-05 |
| WO1993014119A1 (en) | 1993-07-22 |
| EP0621869B1 (en) | 1997-04-23 |
| NO942552L (no) | 1994-09-07 |
| RU94036776A (ru) | 1996-09-27 |
| CA2127248A1 (en) | 1993-07-22 |
| DE69310141D1 (de) | 1997-05-28 |
| ZA9398B (en) | 1993-08-10 |
| HUT70292A (en) | 1995-09-28 |
| JPH07506334A (ja) | 1995-07-13 |
| EP0621869A1 (en) | 1994-11-02 |
| AU3345793A (en) | 1993-08-03 |
| IL104327A0 (en) | 1993-05-13 |
| HU9401993D0 (en) | 1994-09-28 |
| US5629176A (en) | 1997-05-13 |
| NZ246567A (en) | 1996-05-28 |
| NO942552D0 (no) | 1994-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI943231A (fi) | Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnoksia | |
| NO942549L (no) | Humanproteaseinhibitorvariant av Kunitz-type | |
| NZ331895A (en) | Hemoglobin alpha chain polypeptide as inhibitor and stimulator of stem cell proliferation | |
| ZA9394B (en) | A novel human kunitz-type inhibitor and variants thereof | |
| MX9606536A (es) | Proteinas n-terminalmente extendidas expresadas en levaduras. | |
| ATE154938T1 (de) | Inhibitorvariante der menschlichen protease vom kunitz-typ | |
| ATE477020T1 (de) | Prevention und verringerung von ischemia | |
| MD1652F2 (en) | Protein possessing the cytokin - type activity, recombinant DNA-codifyer for such protein, transformed cells and microorganism, expression vector, process for protein obtaining and remedy containing such a protein | |
| DK0466175T3 (da) | Porcint CNP-gen og præcursor-protein | |
| AU5963290A (en) | Inhibition of the n-end rule pathway in living cells | |
| CY1112839T1 (el) | Πεπτιδια χ-κωνοτοξινες που εχουν ενα αμινοτελικο πυρογλουταμικο οξυ | |
| EP1778724B8 (en) | Antiangiogenic peptides | |
| ATE50267T1 (de) | Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren. | |
| PT789761E (pt) | Scf humano, uma respectiva variante de processamento, sua utilizacao farmaceutica | |
| CA2375224A1 (en) | Human antithrombin variants | |
| AU2003259309A8 (en) | Peptides having affinity for a phospholipid and uses | |
| FR2787454B1 (fr) | Inhibiteur de la topoisomerase ii | |
| KR940703855A (ko) | 사람 쿠니즈형 프로테아제 저해제 변이체(a human kunitz-type protease inhibitor variant) | |
| ES2051152B1 (es) | Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados. | |
| TH2482B (th) | สารคล้ายคลึง จี อาร์ เอฟ (grf) |